sms helpline whatsapp - 09881300400

Product enquiry



Each tablet contains: 0.25/0.5 mg Cabergoline


For the treatment of hyperprolactinaemic disorders, either idiopathic or due to pituitary adenomas.

For the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons


For initiation of therapy is 0.25 mg twice a week

Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level

Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease

Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient’s response to each dosage level.